Latest Intelligence on General Business in Israel

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Oxford GlycoSciences/Teva: identifying Israeli opportunities

The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.

Published By Datamonitor
21 Nov 2001
CommentWire
CommentWire

Peptor: investigating additional indications in diabetes

DiaPep277 has already shown strong trial results for type I diabetes, which is in some ways similar to LADA. This makes the new investigation seem worthwhile. Approval would provide a new treatment option for an often-misdiagnosed subcategory of diabetic patients. It would also greatly increase the market potential of the drug, by allowing access to a much larger patient population.

Published By Datamonitor
15 Jan 2002
CommentWire
CommentWire

Mecca Cola: singing a different tune

Mecca Cola is in direct competition with Coca-cola, deliberately appealing to anti-US sentiments. This growing tendency for manufacturers to market themselves on a political positioning to take advantage of consumer concerns creates a loyal customer base that will not be easily swayed.

Published By Datamonitor
09 Jan 2003

« | 1 | » »|

No help is available.